Itaspor-SB Capsule contains Itraconazole 50 mg, a broad-spectrum triazole antifungal agent used for the treatment of various fungal infections. Itraconazole works by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes, thereby disrupting membrane integrity and leading to fungal cell death. Itaspor-SB is indicated for the management of systemic and superficial mycoses, including blastomycosis, histoplasmosis, aspergillosis, onychomycosis, and other dermatophytic infections. The capsule formulation ensures optimal bioavailability when administered orally, with absorption enhanced by gastric acidity. It is recommended to be taken with food to improve absorption. Dosage and duration of therapy depend on the type and severity of the infection, and treatment should be guided by clinical response and laboratory findings. Caution is advised in patients with hepatic impairment, as Itraconazole is metabolized primarily by the liver and may cause hepatotoxicity. Potential drug interactions should be carefully evaluated due to Itraconazole’s inhibition of cytochrome P450 enzymes, which can affect the metabolism of concomitant medications. Common adverse effects include gastrointestinal disturbances, headache, and rash. Regular monitoring of liver function tests is recommended during prolonged therapy. Itaspor-SB Capsule should be used under medical supervision.